{"disease":{"id":"docetaxel","name":"docetaxel"},"drugs":{"marketed":[{"drug_id":"darolutamide","indication_name":"Metastatic castration-sensitive prostate cancer (mCSPC) with docetaxel","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"capecitabine","indication_name":"Treatment of advanced or metastatic breast cancer (with docetaxel)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04393584","title":"FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":538,"lead_sponsor_name":"Blokhin's Russian Cancer Research Center","has_results":false},{"nct_id":"NCT07366528","title":"Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":387,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06374914","title":"Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Dokuz Eylul University","has_results":false},{"nct_id":"NCT04869371","title":"Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Hongqian Guo","has_results":false},{"nct_id":"NCT04023617","title":"A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":72,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT04920747","title":"Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT03589950","title":"Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"The First People's Hospital of Lianyungang","has_results":false},{"nct_id":"NCT04889599","title":"A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Zhuhai Beihai Biotech Co., Ltd","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}